8 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 25.2% per year over the past 5 years.
Operating margin has contracted, at 2.8% in the latest year.
Free cash flow has grown 7.1% per year over the past 5 years.
Financial health
Total debt ($1.7B) exceeds cash ($106M); net debt is $1.6B.
Total debt has grown slower than revenue (17.2% vs 25.2% per year).
Total debt is 3.7× EBITDA.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$3.2B
-$71M
18.8%
2.8%
$219M
$1.7B
$106M
2024
$3.3B
$90M
20.9%
8.1%
$236M
$2.0B
$110M
2023
$3.2B
-$679M
19.5%
-18.7%
$143M
$2.1B
$77M
2022
$3.0B
$69M
19.5%
6.4%
-$18M
$2.2B
$46M
2021
$2.5B
$156M
18.2%
9.2%
$72M
$2.2B
$150M
2020
$1.1B
-$162M
14.9%
6.8%
$156M
$785M
$100M
2019
$530M
-$21M
16.8%
5.5%
$39M
$397M
$77M
2018
$345M
$23M
15.0%
9.0%
$58M
$134M
$25M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$820M
-$16M
13.6%
0.7%
-$27M
$1.8B
$48M
Dec '25
$846M
-$103M
20.3%
-8.7%
$79M
$1.7B
$106M
Sep '25
$820M
$25M
19.7%
7.5%
$67M
$1.8B
$80M
Jun '25
$800M
$15M
19.3%
9.9%
$73M
$1.8B
$69M
Mar '25
$778M
-$7M
15.5%
3.0%
-$58000
$2.0B
$54M
Dec '24
$857M
$50M
22.4%
11.4%
$73M
$2.0B
$110M
Sep '24
$806M
$23M
20.1%
7.9%
$85M
$2.0B
$100M
Jun '24
$806M
$19M
21.0%
6.5%
$117M
$2.1B
$70M
Mar '24
$792M
-$2M
19.9%
6.4%
-$39M
$2.2B
$80M
Dec '23
$858M
-$255M
35.5%
-25.4%
$67M
$2.1B
$77M
Sep '23
$804M
-$454M
13.7%
-57.3%
$22M
$2.2B
$56M
Jun '23
$793M
$14M
15.1%
6.8%
$4M
$2.2B
$45M
Mar '23
$745M
$16M
12.0%
3.5%
$51M
$2.2B
$101M
Dec '22
$780M
-$3M
10.4%
3.4%
-$46M
$2.2B
$46M
Sep '22
$756M
$16M
14.5%
7.0%
$13M
$2.2B
$111M
Jun '22
$728M
$14M
16.2%
8.1%
$26M
$2.2B
$119M
Mar '22
$706M
$42M
15.4%
7.3%
-$11M
$2.2B
$119M
Dec '21
$702M
$23M
15.7%
9.8%
$37M
$2.2B
$150M
Sep '21
$653M
$58M
18.9%
11.6%
-$33M
$2.2B
$337M
Jun '21
$617M
$79M
20.5%
10.6%
$85M
$1.9B
$178M
Valuation over time
How the market has priced AHCO against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 24.4× (Mar '23) to 14.5× (Nov '25).
The price-to-sales ratio has fallen from 0.6× (Mar '23) to 0.4× (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is AHCO growing its revenue and profit?
Over the past 5 years, Adapthealth Corp.'s revenue has grown 25.2% per year. These are computed facts, not advice.
How much debt does AHCO have?
As of FY2025, Adapthealth Corp. reported $1.7B of total debt against $106M of cash.
What is AHCO's profit margin?
In FY2025, gross margin was 18.8%, operating margin 2.8%, and net margin -2.2%.
What is AHCO's P/E ratio?
As of Jun '26, Adapthealth Corp. traded at a price-to-earnings ratio of about 14.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.